Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Denovo Discovers Biomarker for Gene Therapy

publication date: Dec 16, 2021

Denovo Biopharma, a Hangzhou-San Diego precision medicine company, has discovered a genetic biomarker for predicting efficacy of a gene therapy in glioma. Using its proprietary biomarker discovery platform in a retrospective analysis, the company discovered that the novel genetic biomarker is associated with a high rate of response to an investigational gene therapy combination treatment. Recurrent high grade glioma patients with the biomarker responded to DB107, a Denovo candidate that combines a gene therapy and chemotherapy. Denovo acquired the retroviral replicating vector platform from Tocagen in 2020. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital